BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the...
Graviti`s Generic Baclofen Receives Approval in the U.S.
ACIC Pharma's Generic Baclofen Receives Approval in the U.S.
Slayback's Generic Baclofen Receives Approval in the U.S.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
FDA Confirms Paragraph IV Patent Litigation for Baclofen
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) specialty product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.
Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) approval of Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), concentrated formulation for the treatment of spasticity from multiple sclerosis (MS) or patients with spinal cord injuries and other spinal cord diseases.
Mankind Pharma's Generic Baclofen Receives Approval in the U.S.